AstraZeneca Pharma India Limited (ASTRAZEN) Fair Value & Analysis

Healthcare · IN · Market cap ₹211B

A solid business, but screening 82% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (₹2,068). The favourable scenario is already priced in.
• The model range is unusually wide (₹770.00 to ₹2,068). The outcome hinges heavily on assumptions, so read the point estimate with caution.
• Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 2, 2026.

How to read this chart

60‑month range ₹2,426 – ₹10,474 · fair‑value band ₹770.00 – ₹2,068 · the ₹8,100 price screens above the ₹1,495 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 2, 2026.

Which stocks are undervalued right now? Check free Discover now →

Analysis

AstraZeneca Pharma India Limited (ASTRAZEN) currently trades at ₹8,100, while our model-based Fair Value estimate is ₹1,495, implying the stock looks roughly 81.5% overvalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, AstraZeneca Pharma India Limited generated revenue of ₹22.8B at a net margin of 8.2%. Revenue grew 20.4% year over year. It earns a return on equity of 22.8%. The balance sheet holds a net cash position of ₹3.4B. Fundamentals as of Aug 2, 2026

Our scenario range runs from ₹770.00 (bear case) to ₹2,068 (bull case); at ₹8,100, the current price sits above that range. The share trades about 18% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -82%, ASTRAZEN screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (₹1,768) versus Growth DCF (₹220.27). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally.

Full company description

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company has a strategic collaboration with Leica Biosystems and Daiichi Sankyo Company, Limited for the development of an immunohistochemistry assay and an image analysis algorithm for the TROP2 NMR biomarker in non-small cell lung cancer. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

AstraZeneca Pharma India Limited reported revenue of ₹22.8B in FY2026 versus ₹8.1B in FY2022, a compound +29.6%/yr. Reported net income was ₹1.9B in FY2026, compounding +32.1%/yr from FY2022.

ASTRAZEN screens 82% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 654 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 2, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.